Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

NCT02603315 | Completed

• 1 other identifier: DR-81
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Conditions

Malignant Pleural Mesotheliomas

Outcome Measures

Primary Outcomes (1)

• to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival

  The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

  3-4 months

Secondary Outcomes (1)

• assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74

  3-4 months

Interventions

marker CD74 and vascular endothelial growth factor VEGF OTHER

correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment

Eligibility Criteria

• Age: 39 Years - 84 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Egyptian patients with confirmed malignant pleural mesothelioma

You may qualify if:

• Histopathological confirmation of malignant pleural mesothelioma .
• Full clinical data.
• Availability for follow up: Personal communication will be attempted in order to collect missing information.
• The files of all patients will be reviewed to analyze the following :
• Operative data if done .
• Pathological review and immunohistochemistry.
• Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)
• Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\\S and MRI ).
• Treatment protocols applied: Radiotherapy and Chemotherapy.
• Response and survival after treatment .

You may not qualify if:

• cases not receive chemotherapy ,on available of evaluation after treatment

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University Hospital

Cairo, Egypt

Location

MeSH Terms

Conditions

Mesothelioma, Malignant

Interventions

Vascular Endothelial Growth Factor A

Condition Hierarchy (Ancestors)

Mesothelioma; Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Mesothelial; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Pleural Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Vascular Endothelial Growth Factors; Angiogenic Proteins; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Study Officials

• Amr S Saad, MD

  Ain Shams University

  STUDY DIRECTOR

• Mahmoud Ellithy, MD

  Ain Shams University

  STUDY CHAIR

• Doaa Atef, MD

  Ain Shams University

  STUDY DIRECTOR

• Hoda Abougabal, MD

  Ain Shams University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor in clinical oncology and nuclear medicine department

Study Record Dates

• First Submitted: October 28, 2015
• First Posted: November 11, 2015
• Study Start: October 1, 2015
• Primary Completion: May 1, 2016
• Study Completion: May 1, 2016
• Last Updated: June 1, 2016

Record last verified: 2015-10

Locations

EG (1)